Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer

NCT01693419 is registered in ClinicalTrials.gov with Hallym University Medical Center as lead sponsor.

NCT NCT01693419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Hallym University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
December 31, 2016
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas neoplasms